Literature DB >> 8923292

Immunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV.

M Mackett1, C Cox, S D Pepper, J F Lees, B A Naylor, N Wedderburn, J R Arrand.   

Abstract

Epstein-Barr virus (EBV) is the cause of infectious mononucleosis and is associated with a variety of life-threatening diseases in humans. Therefore the development of an effective vaccine is an important objective. Many of the initial studies of vaccine efficacy analyse the ability of vaccine preparations to prevent the induction of lymphomas in cottontop tamarins by the B95-8 strain of EBV. We used a vaccinia virus recombinant expressing gp340, vMA1, tested previously in the cotton-top tamarin, to evaluate a common marmoset model in which the challenge virus, M81, resembles more closely the wild-type strains of EBV in the general population than does the standard B95-8 strain. We characterised the M81 strain of EBV with respect to the sequence of its gp340/220 gene and in regard to the presence of a region deleted in B95-8. Replication of the challenge virus in the group vaccinated with vMA1 was decreased when compared to control groups.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923292     DOI: 10.1002/(SICI)1096-9071(199611)50:3<263::AID-JMV9>3.0.CO;2-7

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  11 in total

1.  Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.

Authors:  Kendra A Young; Andrew P Herbert; Paul N Barlow; V Michael Holers; Jonathan P Hannan
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

2.  Candidate vaccines for Epstein-Barr virus.

Authors:  D J Moss; A Suhrbier; S L Elliott
Journal:  BMJ       Date:  1998-08-15

3.  An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA.

Authors:  Sophia Pavlova; Regina Feederle; Kathrin Gärtner; Walter Fuchs; Harald Granzow; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

4.  Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.

Authors:  Gabriela M Escalante; Lorraine Z Mutsvunguma; Murali Muniraju; Esther Rodriguez; Javier Gordon Ogembo
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

5.  A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.

Authors:  Xinle Cui; Zhouhong Cao; Goutam Sen; Gouri Chattopadhyay; Deborah H Fuller; James T Fuller; Dustin M Snapper; Andrew L Snow; James J Mond; Clifford M Snapper
Journal:  Vaccine       Date:  2013-05-09       Impact factor: 3.641

6.  Characterization of natural killer cells in tamarins: a technical basis for studies of innate immunity.

Authors:  Tomoyuki Yoshida; Akatsuki Saito; Yuki Iwasaki; Sayuki Iijima; Terue Kurosawa; Yuko Katakai; Yasuhiro Yasutomi; Keith A Reimann; Toshiyuki Hayakawa; Hirofumi Akari
Journal:  Front Microbiol       Date:  2010-12-08       Impact factor: 5.640

Review 7.  The antiviral prophylaxis of post-transplant lymphoproliferative disorder.

Authors:  C L Davis
Journal:  Springer Semin Immunopathol       Date:  1998

Review 8.  Epstein-barr virus vaccines.

Authors:  Jeffrey I Cohen
Journal:  Clin Transl Immunology       Date:  2015-01-23

Review 9.  The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.

Authors:  Cong Sun; Xin-Chun Chen; Yin-Feng Kang; Mu-Sheng Zeng
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

10.  Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge.

Authors:  Xinle Cui; Zhouhong Cao; Yuriko Ishikawa; Sara Cui; Ken-Ichi Imadome; Clifford M Snapper
Journal:  Vaccines (Basel)       Date:  2021-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.